AIDS Vaccine for Asia Network (AVAN): Expanding the Regional Role in Developing HIV Vaccines

1. BuchbinderSP

MehrotraDV

DuerrA

FitzgeraldDW

MoggR

2008 Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372 1881 1893

2. FauciAS

JohnstonMI

DieffenbachCW

BurtonDR

HammerSM

2008 HIV vaccine research: the way forward. Science 321 530 532

3. Rerks-NgarmS

PitisuttithumP

NitayaphanS

KaewkungwalJ

ChiuJ

2009 Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N Engl J Med 361 2209 2220

4. KlausnerRD

FauciAS

CoreyL

NabelGJ

GayleH

2003 Medicine. The need for a global HIV vaccine enterprise. Science 300 2036 2039

5. KaleebuP

AbimikuA

El-HalabiS

Koulla-ShiroS

MamotteN

2008 African AIDS vaccine programme for a coordinated and collaborative vaccine development effort on the continent. PLoS Med 5 e236 doi:10.1371/journal.pmed.0050236

6. Coordinating Committee of the Global HIV/AIDS Vaccine Enterprise 2005 The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan. PLoS Med 2 e25 doi:10.1371/journal.pmed.0020025

7. UNAIDS 2010 Joint United Nations Programme on HIV/AIDS homepage. Available: http://www.unaids.org/en/CountryResponses/Regions/Asia.asp. Accessed 17 August 2010

8. Commission on AIDS in Asia 2008

MaraisH

Redefining AIDS in Asia: crafting an effective response. Report of the Commission on AIDS in Asia. New Delhi Oxford University Press

9. LuL

JiaM

MaY

YangL

ChenZ

2008 The changing face of HIV in China. Nature 455 609 611

10. WangW

JiangS

LiS

YangK

MaL

2008 Identification of subtype B, multiple circulating recombinant forms and unique recombinants of HIV type 1 in an MSM cohort in China. AIDS Res Hum Retroviruses 24 1245 1254

11. HemelaarJ

GouwsE

GhysPD

OsmanovS

2006 Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20 W13 W23

12. DeshpandeA

JauvinV

PinsonP

JeannotAC

FleuryHJ

2009 Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. AIDS Res Hum Retroviruses 25 633 635

13. WirachsilpP

KantakamalakulW

FoongladdaS

ChuenchitraT

KohriangudomS

2007 Surveillance of subtype and genetic variation of the circulating strains of HIV-1 in Thailand. Southeast Asian J Trop Med Public Health 38 814 827

14. PitisuttithumP

2008 HIV vaccine research in Thailand: lessons learned. Expert Rev Vaccines 7 311 317

15. ShaoY

LiT

ShenX

ZhangJ

ZhuH

2008 The safety and immunogenicity of the replicative Tiantan vaccinia HIV vaccine in phase I clinical trial. Poster No P13-18, AIDS Vaccine 2008, Cape Town, South Africa, Oct 13–16

16. HuangX

LuB

YuW

FangQ

LiuL

2009 A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. PLoS ONE 4 e4180 doi:10.1371/journal.pone.0004180

17. DaiK

LiuY

LiuM

XuJ

HuangW

2008 Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes. Vaccine 26 5062 5071

18. MehendaleS

van LunzenJ

ClumeckN

RockstrohJ

VetsE

2008 A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine. AIDS Res Hum Retroviruses 24 873 880

19. RamanathanVD

KumarM

MahalingamJ

SathyamoorthyP

NarayananPR

SolomonS

2009 A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV-1 subtype C modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Human Retroviruses 25 1107 1116

20. BerkleyS

2008 HIV vaccine trials in India. Nat Biotechnol 26 495 author reply 496

21. International AIDS Vaccine Initiative 2010 Working with communities: India. Available: http://www.iavi.org/working-with-communities/country-programs/Pages/india.aspx. Accessed 17 August 2010

22. KelleherAD

PulsRL

BebbingtonM

BoyleD

FfrenchR

2006 A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS 20 294 297

23. De RoseR

FernandezCS

SmithMZ

BattenCJ

AlcantaraS

2008 Control of viremia following immunotherapy of SIV-infected macaques with peptide pulsed blood. PLoS Pathog 4 e1000055 doi:10.1371/journal.ppat.1000055

24. De RoseR

ZelikinA

JohnstonAPR

SextonA

ChongSF

2008 Binding, internalisation and antigen presentation of vaccine-loaded nanoengineered capsules in blood. Advanced Materials 20 4698 4703

25. StratovI

ChungA

KentSJ

2008 Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol 82 5450 5459

26. ZaundersJJ

MunierML

SeddikiN

PettS

IpS

2009 High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40). J Immunol 183 2827 2836

27. HiroiT

GotoH

SomeyaK

YanagitaM

HondaM

2001 HIV mucosal vaccine: nasal immunization with rBCG-V3J1 induces a long term V3J1 peptide-specific neutralizing immunity in Th1- and Th2-deficient conditions. J Immunol 167 5862 5867

28. KawadaM

TsukamotoT

YamamotoH

IwamotoN

KuriharaK

2008 Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial. J Virol 82 10199 10206

29. EsparzaJ

1999 AIDS vaccine research in Asia: needs and opportunities. Report from a UNAIDS/WHO/NIID meeting Tokyo, 28–30 October 1998. AIDS 13 UNAIDS 1 UNAIDS 13

30. ExclerJL

PitisuttithumP

Rerks-NgarmS

ShaoY

ZhangL

2008 Expanding research capacity and accelerating AIDS vaccine development in Asia. Southeast Asian J Trop Med Public Health 39 766 784

31. Rerks-NgarmS

PitisuttithumP

GangulyN

ZhangLi

TamashiroH

2010 Defining the objectives of the AIDS Vaccine for Asia Network: WHO-UNAIDS/Global HIV Vaccine Enterprise regional consultation on expanding AIDS vaccine research and development capacity in Asia. Curr Opin HIV AIDS 5 435 452

32. LenihanF

1993 China and Thailand to start trials of AIDS vaccines. BMJ 306 1564 1565

33. PitisuttithumP

GilbertP

GurwithM

HeywardW

MartinM

2006 Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194 1661 1671

34. ThongcharoenP

SuriyanonV

ParisRM

KhamboonruangC

de SouzaMS

2007 A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr 46 48 55

35. EarlPL

CotterC

MossB

VanCottT

CurrierJ

2009 Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine 27 5885 5895

36. De RoseR

CheaS

DaleCJ

ReeceJ

FernandezCS

2005 Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques. Vaccine 23 1949 1956

37. ShaoY

LiT

WolfH

LiuY

WangH

2009 The safety and immunogenicity of HIV-1 vaccines based on DNA and replication competent vaccinia vector in phase I clinical trial. Poster NoP14-15LB, AIDS Vaccine 2009, Paris, Oct 19–22

38. KumarS

AggarwalP

VajpayeeM

PandeyRM

SethP

2006 Development of a candidate DNA/MVA HIV-1 subtype C vaccine for India. Vaccine 24 2585 2593